Affiliation:
1. University of Texas Southwestern Medical Center at Dallas, Co-Medical Director Radiant Research – Dallas, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235-5360 USA.
Abstract
Recent advances in the understanding of the pathophysiology and aggressive treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis have dramatically changed the outcomes of patients with these diseases over the past 7 years. Much of the progress in therapy is due to the change in the treatment paradigm in which early, aggressive therapy has become the norm and the introduction of therapies that target the disease processes, specifically the overproduction of tumor necrosis factor-α. Etanercept was the first anti-tumor necrosis factor-α therapy approved for use in rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. It has been shown to have an excellent risk:benefit ratio in clinical trials as well as postmarketing surveillance. However, there has been limited information regarding the safety and efficacy of etanercept in patients aged 65 years or over, which is the focus of this review.
Subject
Geriatrics and Gerontology,General Medicine
Reference87 articles.
1. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
2. MitchellD: Epidemiology. In:Rheumatoid Arthritis: Etiology, Diagnosis, Management.Utsinger PD, Zvaifler NJ, Ehrlich GE (Eds). JB Lippincott, PA, USA,133–137 (1985).
3. RobinsonH: Multidisciplinary ambulatory care for the elderly arthritis patient. In:Arthritis and the Elderly.Moskowitz HG, Haug MR (Eds). Springer, NY, USA,146–149 (1986).
4. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline
5. Direct and Indirect Costs of Rheumatoid Arthritis to an Employer
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献